Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
NCT03195400 · View on ClinicalTrials.gov ↗
Study Summary
Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incretin system and hepatic insulin resistance in obese adolescents. The long-term goal of this study is to generate information on both the genetics as well as the pathophysiology of Type 2 Diabetes in Youth, which ultimately might guide the investigators towards better preventive and treatment avenues.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Oral Glucose Tolerance Test
- DIAGNOSTIC_TEST Hyperglycemic Clamp
- DIAGNOSTIC_TEST Isoglycemic Intravenous Glucose Test
- DIAGNOSTIC_TEST Hyperinsulinemic Euglycemic Clamp and 2H20
Study Locations (1)
Connecticut
- Yale University — New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2022-08-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03195400
The ClinicalTrials.gov registry entry for NCT03195400 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,283 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with T2D appearing as the primary indexed condition, and to 4 interventions — of which Oral Glucose Tolerance Test is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03195400 reports 1 study location spanning 1 distinct geographic area — top geographies include Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03195400 about?
NCT03195400 is a clinical study titled "Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes". Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incret...
What is the current status of trial NCT03195400?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2017-03-01. Estimated completion is 2022-08-12.
What conditions does trial NCT03195400 study?
This clinical trial studies the following conditions: T2D, IGT - Impaired Glucose Tolerance. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03195400?
The interventions under investigation include: Oral Glucose Tolerance Test (DIAGNOSTIC_TEST), Hyperglycemic Clamp (DIAGNOSTIC_TEST), Isoglycemic Intravenous Glucose Test (DIAGNOSTIC_TEST), Hyperinsulinemic Euglycemic Clamp and 2H20 (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03195400?
This trial is sponsored by Yale University, which has 1,283 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03195400 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.